Teleflex’s (TFX) “Neutral” Rating Reaffirmed at Piper Sandler

Piper Sandler reissued their neutral rating on shares of Teleflex (NYSE:TFX) in a research report report published on Friday, MarketBeat Ratings reports. The firm currently has a $140.00 target price on the medical technology company’s stock, down from their previous target price of $255.00.

A number of other brokerages also recently weighed in on TFX. Royal Bank of Canada cut their price target on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a report on Friday, November 1st. StockNews.com raised shares of Teleflex from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Citizens Jmp downgraded shares of Teleflex from an “outperform” rating to a “market perform” rating in a report on Thursday. Needham & Company LLC reissued a “hold” rating on shares of Teleflex in a report on Monday, December 16th. Finally, Truist Financial cut their price target on shares of Teleflex from $227.00 to $200.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. Nine investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Teleflex has a consensus rating of “Hold” and a consensus target price of $196.83.

Teleflex Stock Performance

Shares of TFX opened at $132.58 on Friday. The firm has a 50-day moving average price of $175.44 and a 200 day moving average price of $205.04. The firm has a market capitalization of $6.16 billion, a PE ratio of 26.36, a P/E/G ratio of 1.73 and a beta of 1.16. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37. Teleflex has a 52-week low of $130.60 and a 52-week high of $249.90.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, February 27th. The medical technology company reported $3.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.86 by $0.03. The firm had revenue of $795.40 million during the quarter, compared to analyst estimates of $813.24 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. On average, sell-side analysts anticipate that Teleflex will post 13.98 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 17th. Shareholders of record on Friday, March 7th will be paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 1.03%. The ex-dividend date is Friday, March 7th. Teleflex’s dividend payout ratio is presently 27.04%.

Institutional Trading of Teleflex

A number of hedge funds have recently bought and sold shares of the company. Headlands Technologies LLC purchased a new stake in shares of Teleflex in the fourth quarter worth approximately $29,000. Avior Wealth Management LLC lifted its position in shares of Teleflex by 190.6% in the third quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company’s stock worth $38,000 after purchasing an additional 101 shares in the last quarter. Ashton Thomas Securities LLC purchased a new stake in shares of Teleflex in the third quarter worth approximately $40,000. True Wealth Design LLC lifted its position in shares of Teleflex by 16,600.0% in the third quarter. True Wealth Design LLC now owns 167 shares of the medical technology company’s stock worth $41,000 after purchasing an additional 166 shares in the last quarter. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Teleflex in the third quarter worth approximately $54,000. 95.62% of the stock is owned by hedge funds and other institutional investors.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.